Chapter 53. Chronic Allograft Nephropathy

  1. Donald A. Molony MD5,6 and
  2. Jonathan C. Craig MD, PhD7,8
  1. Bengt C. Fellström MD, PhD1,2,
  2. Alan Jardine MD3 and
  3. Hallvard Holdaas MD4

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch53

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Fellström, B. C., Jardine, A. and Holdaas, H. (2008) Chronic Allograft Nephropathy, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch53

Editor Information

  1. 5

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 6

    Houston Medical School, Houston, Texas, USA

  3. 7

    School of Public Health, University of Sydney, Australia

  4. 8

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. 1

    Department of Medicine, Renal Unit, University Hospital, Uppsala, Sweden

  2. 2

    Department of Medical Sciences, Nephrology Unit, University Hospital, Uppsala, Sweden

  3. 3

    Nephrology & Transplantation, BHF Cardiovascular Research Centre, University of Glasgow, G12 8TA, Glasgow, United Kingdom

  4. 4

    Department of Nephrology, Rikshospitalet, Oslo, Norway

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • chronic allograft nephropathy (CAN);
  • course of CAN;
  • antibody-mediated rejection;
  • immunological injury;
  • acute rejection episodes;
  • subclinical rejection;
  • allo- and innate immune reactivity and nonimmune factors;
  • clinical factors and progression of CAN;
  • CNI nephrotoxicity


This chapter contains sections titled:

  • Definition

  • The course of CAN

  • Immunological injury

  • Clinical factors and progression of CAN

  • BK virus nephropathy

  • Prevention and treatment

  • Overall impact of CAN

  • Summary and conclusion

  • References